Filing Flows › Tela Bio (TELA) › Q4 2025
Tela Bio (TELA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 25, 2026
Tela Bio (TELA) reported revenue of $20.9M for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and +0.9% from the quarter before. Operating margin was -31.9%, net loss $9.0M (43.3% of revenue).
Tela Bio, Q4 2025: revenue $20.9M (+18% year over year), operating margin -31.9%, net loss $9.0M, operating cash flow −$4.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.9M | +0.9% | +18% |
| Operating profit | −$6.6M | — | — |
| Net earnings | −$9.0M | — | — |
| Operating cash flow | −$4.9M | — | — |
What changed
Revenue was $20.9M in Q4 2025, up 18% year over year and up 1% from the previous quarter.
Gross margin was 65.9%, up 2.3 points from Q4 2024. Operating costs exceeded revenue by $6.6M, an operating margin of -31.9%. Operating expenses grew 4% against revenue growth of 18%. The quarter ended with a net loss of $9.0M, wider than the previous quarter's $8.6M loss.
Operating cash flow was −$4.9M. Non-cash charges added back $130K of depreciation and $812K of share-based compensation. Working capital and other items added $3.2M. Capital expenditures of $91K exceeded it, leaving free cash flow of −$5.0M.
Questions
What was Tela Bio's revenue in the fourth quarter 2025?
Tela Bio (TELA) reported revenue of $20.9M for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and +0.9% from the quarter before.
Was Tela Bio profitable in the fourth quarter 2025?
Operating loss was $6.6M (-31.9% of revenue) and net loss $9.0M.
Source: Tela Bio 10-K on SEC EDGAR.